EA202190567A1 - Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба - Google Patents

Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба

Info

Publication number
EA202190567A1
EA202190567A1 EA202190567A EA202190567A EA202190567A1 EA 202190567 A1 EA202190567 A1 EA 202190567A1 EA 202190567 A EA202190567 A EA 202190567A EA 202190567 A EA202190567 A EA 202190567A EA 202190567 A1 EA202190567 A1 EA 202190567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nintedanib
salts
formulations
inhaled
indolinone
Prior art date
Application number
EA202190567A
Other languages
English (en)
Inventor
Марк Уилльям Сербер
Стефен Фам
Original Assignee
Авалин Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авалин Фарма Инк. filed Critical Авалин Фарма Инк.
Publication of EA202190567A1 publication Critical patent/EA202190567A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к составам нинтеданиба и его солям, производным соединениям и солям индолинона для аэрозолизации и к применению таких составов для предотвращения появления различных фиброзных, онкогенных, сосудистых и вирусных инфекционных заболеваний или их лечения, в том числе заболеваний, связанных с легкими, сердцем, почками, печенью, органами зрения и центральной нервной системой, а также в местах хирургического вмешательства. Описанные здесь составы и варианты их доставки обеспечивают эффективную локальную доставку производных соединений нинтеданиба или индолинона или их солей. Способы включают ингаляционные процедуры, показания и процессы изготовления и применения описанных здесь композиций. Также приведены способы выявления соединений и показаний, полезных при изменении состава и ингаляционном введении.
EA202190567A 2018-08-22 2019-08-22 Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба EA202190567A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721522P 2018-08-22 2018-08-22
PCT/US2019/047775 WO2020041631A1 (en) 2018-08-22 2019-08-22 Specially formulated compositions of inhaled nintedanib and nintedanib salts

Publications (1)

Publication Number Publication Date
EA202190567A1 true EA202190567A1 (ru) 2021-05-26

Family

ID=69584104

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190567A EA202190567A1 (ru) 2018-08-22 2019-08-22 Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба

Country Status (12)

Country Link
US (2) US11123290B2 (ru)
EP (1) EP3841090A4 (ru)
JP (1) JP2021534079A (ru)
KR (1) KR20210047331A (ru)
CN (1) CN112867707A (ru)
AU (1) AU2019324188A1 (ru)
BR (1) BR112021003071A2 (ru)
CA (1) CA3109823A1 (ru)
EA (1) EA202190567A1 (ru)
IL (1) IL280932A (ru)
MX (1) MX2021001814A (ru)
WO (1) WO2020041631A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017728A1 (en) * 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019067866A1 (en) 2017-09-29 2019-04-04 Crititech, Inc. GLUCOCORTICOID PARTICLES AND THEIR USE
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2020232236A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
US20240050374A1 (en) * 2020-12-07 2024-02-15 Mannkind Corporation Method and Composition for Treating Pulmonary Fibrosis
CN114617860A (zh) * 2020-12-14 2022-06-14 南京华威医药科技集团有限公司 一种含尼达尼布的吸入液及其制备方法
US20220296511A1 (en) * 2021-03-18 2022-09-22 Board Of Regents, The University Of Texas System Compositions for delivery of drug combinations to treat lung disease
CN114869866B (zh) * 2022-05-05 2024-02-20 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法
WO2023235267A2 (en) * 2022-05-28 2023-12-07 Avalyn Pharma Inc. Nintedanib and nintedanib combination dry powder compositions and uses
WO2024003380A1 (en) * 2022-06-30 2024-01-04 Icm (Institut Du Cerveau Et De La Moelle Épinière) Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
CN115400082A (zh) * 2022-08-19 2022-11-29 浙江萃泽医药科技有限公司 含铁离子螯合剂的雾化吸入混悬制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
MX2009009760A (es) 2007-03-13 2009-09-24 Oculus Innovative Sciences Inc Soluciones antimicrobiales que contienen monoxido de dicloro y metodos para hacer y utilizar las mismas.
WO2009086470A2 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
JP2013502416A (ja) * 2009-08-19 2013-01-24 エムペックス ファーマスーティカルズ，インコーポレイテッド 慢性閉塞性肺疾患治療用のエアロゾル化された抗生物の使用
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
WO2015017728A1 (en) * 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US9770443B2 (en) * 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN110062625A (zh) * 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法

Also Published As

Publication number Publication date
US20220000772A1 (en) 2022-01-06
MX2021001814A (es) 2021-07-02
US20200060968A1 (en) 2020-02-27
US12090225B2 (en) 2024-09-17
KR20210047331A (ko) 2021-04-29
CA3109823A1 (en) 2020-02-27
US11123290B2 (en) 2021-09-21
IL280932A (en) 2021-04-29
WO2020041631A1 (en) 2020-02-27
EP3841090A1 (en) 2021-06-30
EP3841090A4 (en) 2022-10-19
CN112867707A (zh) 2021-05-28
JP2021534079A (ja) 2021-12-09
BR112021003071A2 (pt) 2021-05-11
AU2019324188A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
EA202190567A1 (ru) Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба
NZ717528A (en) Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2020086759A3 (en) Composition and method for treating the lungs
CY1121698T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
RU2013156378A (ru) 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
NZ722927A (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
NZ766322A (en) Patient management system
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112021018707A2 (pt) Formulações compreendendo melflufeno
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
CN105311081A (zh) 山海丹野菊花注射液在雾化吸入、喷瓶气雾、直肠给药的应用及方法
EP4400119A3 (en) Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)
EA201792565A1 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
EA201792237A1 (ru) Фармацевтические составы
EP4389218A3 (en) Composition for treating joint disease and kit containing same
RU2012116226A (ru) Бронхолитическое средство на основе простагландина
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
AR116397A1 (es) Composiciones formuladas especialmente de nintedanib inhalado y sales de nintedanib